Exciting Virtual Events from Kura Oncology on FTI Program
Kura Oncology, Inc. (NASDAQ: KURA), a forward-thinking biopharmaceutical company dedicated to advancing precision cancer medicines, is poised to host two pivotal virtual events focusing on its farnesyl transferase inhibitor (FTI) program. These sessions aim to highlight the company’s innovative approaches in managing solid tumors and hematological cancers.
Event Highlights and Objectives
The first event will focus on the preclinical aspects of Kura's FTI program, showcasing the exciting potential of combining FTIs with various targeted therapies. This exploration is crucial in understanding how these combinations can redefine treatment paradigms.
FTI Preclinical Program Review: Synergistic Combinations
Set for September 16, the preclinical program review will detail the mechanisms of action behind FTIs, highlighting how they synergistically work with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors. This discussion is aimed at demonstrating their transformational potential for treating solid tumors.
Insight into Clinical Data from ESMO Congress 2025
The second event, scheduled for October 18, will delve into the clinical data shared at the recent ESMO Congress 2025. This session will offer a captivating look into the initial clinical insights from KO-2806, Kura’s next-generation FTI, which aims to combat resistance mechanisms prevalent in cancer treatment.
Details of the Presentations
During the ESMO Congress 2025, Kura will present three poster sessions highlighting groundbreaking research:
First Results from KO-2806 in RCC
The preliminary results from the FIT-001 phase 1 trial of the FTI KO-2806 combined with cabozantinib in renal cell carcinoma (RCC) will be discussed, offering attendees insights into promising treatment combinations.
Study of KO-2806 in Advanced Solid Tumors
Further, a phase 1 study of KO-2806 as a standalone treatment for advanced solid tumors will be presented, showcasing its efficacy and safety profile.
Combination Therapy in Head and Neck Cancer
Lastly, findings regarding the combination of Tipifarnib and Alpelisib in recurrent/metastatic head and neck squamous cell carcinoma will be shared, summarizing key outcomes from the KURRENT-HN trial.
About Kura Oncology
Kura Oncology stands at the forefront of cancer treatment innovation, focusing on small molecule drug candidates that target critical signaling pathways involved in various cancers. The company's emphasis on developing therapies like ziftomenib aims to address unmet medical needs in hematologic malignancies and solid tumors.
Frequently Asked Questions
What are the main topics of Kura Oncology's upcoming events?
The events will cover Kura's preclinical and clinical findings related to its farnesyl transferase inhibitor program, specifically focusing on new combinations and data presented at the ESMO Congress 2025.
When will the virtual events take place?
The events are scheduled for September 16 and October 18, with detailed presentations on preclinical and clinical data.
How can investors access the events?
Live audio webcasts will be available in the Investors section of Kura's website, with replays accessible post-event.
What is KO-2806?
KO-2806 is Kura's next-generation farnesyl transferase inhibitor designed to address resistance mechanisms in cancer treatment.
What significance does Kura Oncology place on combination therapies?
Kura believes that combining FTIs with targeted therapies has the potential to enhance treatment efficacy, particularly in solid tumors.
